Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Uterine Fibroid Drug Esmya Investigated Due to Severe Liver Injuries

February 22, 2018 By Law Offices of Thomas J. Lamb, P.A.


About Esmya

Esmya (ulipristal acetate) is indicated for the treatment of severe symptoms caused by uterine fibroids — or noncancerous growths in the uterus — in women of reproductive age.

While Esmya is currently available in Europe, it is still pending FDA approval in the U.S.

The active ingredient, ulipristal acetate is the same as that of Ella, an emergency birth control medication that is approved in the U.S.  However, a key difference between the two medications is the dose amount and frequency.  While Ella is a 30mg tablet meant to be used once, Esmya is a 5mg tablet to be used once daily for treatment courses of up to 3 months each.

 

Reports of Severe Liver Injury

The European Drug Label for Esmya lists “Hepatic impairment” in the “Special warnings and precautions for use” section.

Here is an alarming excerpt from this section:

During the post-marketing experience, cases of liver injury and hepatic failure were reported.  During treatment, liver function tests should be performed at least monthly. In addition liver testing 2- 4 weeks after treatment has stopped is recommended. If a patient shows signs or symptoms compatible with liver injury (nausea, vomiting, right hypochondrial pain, anorexia, asthenia, jaundice, etc.), the patient should be investigated immediately, and liver function tests performed.

Four cases of severe liver injuries in patients using the drug have already been reported to the European Medicines Agency (EMA), three of which resulted in liver transplants.

 

Ongoing Investigation

In December 2017, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began their investigation of the association between Esmya and liver failure.

They provide the following information in their investigation announcement letter:

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has made an initial assessment of the cases of liver injury and considered that Esmya could be the cause.

Given the seriousness of the observed liver injury and its possible link to the medicine, a more in depth review is warranted.

While the investigation is still underway, the EMA has advised healthcare providers to refrain from initiating treatment with Esmya.  They also encouraged doctors to closely monitor the liver function of patients already taking the drug to see if stopping treatment is necessary.

We will continue to monitor the medical literature here and abroad for developments in the PRAC’s investigation of Esmya, and report accordingly.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: EMA, esmya, esmya side effects, European Medicines Agency, hepatic failure, liver failure, liver injury, liver transplants, Pharmacovigilance Risk Assessment Committee, PRAC, ulipristal acetate, uterine fibroids treatments

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.